Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients.
DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
After the targeting moiety has bound the specific surface marker, the cell-penetrating peptide makes a channel at the cell membrane, allowing the PDC to infiltrate the cells of the targeted tissue.
In addition, in April 2024, Novartis, which already has two FDA-approved PDC drugs, expanded its collaboration with PeptiDream to further develop peptide-drug conjugates in a deal exceeding USD 2. ...
In addition, in April 2024, Novartis, which already has two FDA-approved PDC drugs, expanded its collaboration with PeptiDream to further develop peptide-drug conjugates in a deal exceeding USD 2. ...
The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...
The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback